Japan approval rush includes Xeljanz, Acofide, Nouriast and Onglyza
This article was originally published in Scrip
Executive Summary
Less than two weeks after giving a preliminary nod to Xeljanz (tofacitinib), Japan has granted a formal approval to the novel Pfizer rheumatoid arthritis drug, only the second to be given worldwide after that in the US last November.